ERBB2 and breast cancer: The CDK pathway could mediate resistance to HER2 pathway blockade.Combination therapies with CDK4/6-inhibitors and HER2-inhibitors for HER2-positive BC showed encouraging results and are continued to be investigated.Results from ongoing trials such as PATRICIA II, PATINA, and NA-PHER2 could provide important answers.